

BIOGRAPHICAL SKETCH (CURRICULUM VITAE)

NAME: Cadegiani, Flavio A. -
 DATE OF BIRTH: February 24, 1985
 PLACE OF BIRTH: São Bernardo do Campo, SP,
 Brazil

POSITION TITLE

MD (2008)
 Department of Medicine at
 University of Brasilia, DF, Brazil.

MSc (2016)
 Division of Endocrinology
 Department of Medicine
 Federal University of Sao Paulo, SP, Brazil.

PhD (2018)
 Division of Endocrinology
 Department of Medicine
 Federal University of Sao Paulo, SP, Brazil.

PhD Supervisor & Researcher (2018-)
 Division of Endocrinology
 Department of Medicine
 São Paulo Hospital
 Federal University of Sao Paulo, SP, Brazil.

Founder, CEO, and Medical Director
 Corpometria Institute, Brasilia DF, Brazil

CLINICAL TRAINING

INSTITUTION AND LOCATION	DEGREE	YEAR(s)	FIELD OF STUDY
University of Brasilia (UnB) School of Medicine, Brasilia, Brazil	MD	2008	-
University Hospital of Brasilia / University of Brasilia / UnB, Brasilia, Brazil	Specialist	2010	Internal Medicine
Hospital de Base do Distrito Federal, Brasilia, Brazil	Specialist	2012	Endocrinology
Brazilian Society of Endocrinology and Metabolism, Brazil	Board Certification	2013	Endocrinology

RESEARCH

INSTITUTION AND LOCATION	DEGREE	YEAR(s)	FIELD OF STUDY
University of Brasilia (UnB) School of Medicine, Brasilia, Brazil	MD	2008	-
Federal University of Sao Paulo, São Paulo, Brazil	MSc	2016	Clinical Endocrinology
Federal University of Sao Paulo, São Paulo, Brazil	PhD	2018	Clinical Endocrinology

CNPQ-LATTES: <http://lattes.cnpq.br/1780670748106294>

BOOK

Overtraining Syndrome in Athletes. 1st edition. 415 pages. Author. United Kingdom. Springer Nature. In press (planned to be published in October/2020).

RECENT PUBMED INDEXED SCIENTIFIC PUBLICATIONS

Cadegiani FA, Goren A, Wambier CG, McCoy J. Early COVID-19 therapy with azithromycin plus nitazoxanide, ivermectin or hydroxychloroquine in outpatient settings significantly improved COVID-19 outcomes compared to known outcomes in untreated patients. *New Microbes New Infect.* 2021 Sep;43:100915. doi: 10.1016/j.nmni.2021.100915. Epub 2021 Jul 7. PMID: 34249367; PMCID: PMC8262389.

McCoy J, Goren A, Cadegiani FA, Vaño-Galván S, Kovacevic M, Situm M, Shapiro J, Sinclair R, Tosti A, Stanimirovic A, Fonseca D, Dorner E, Onety DC, Zimerman RA, Wambier CG. Proxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial. *Front Med (Lausanne).* 2021 Jul 19;8:668698. doi: 10.3389/fmed.2021.668698. PMID: 34350193; PMCID: PMC8326462.

Cadegiani FA, McCoy J, Gustavo Wambier C, Vaño-Galván S, Shapiro J, Tosti A, Zimerman RA, Goren A. Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial. *Cureus.* 2021 Feb 22;13(2):e13492. doi: 10.7759/cureus.13492. PMID: 33633920; PMCID: PMC7899267.

Cadegiani FA, McCoy J, Gustavo Wambier C, Goren A. Early Antiandrogen Therapy With Dutasteride Reduces Viral Shedding, Inflammatory Responses, and Time-to-Remission in Males With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Interventional Trial (EAT-DUTA AndroCoV Trial - Biochemical). *Cureus.* 2021 Feb 1;13(2):e13047. doi: 10.7759/cureus.13047. PMID: 33643746; PMCID: PMC7885746.

Nguyen C, Yale K, Ghigi A, Zheng K, Mesinkovska NA, Wambier CG, Cadegiani FA, Goren A. SARS-CoV-2 infection in patients with thyroid disease: a cross-sectional

study. *Ann Thyroid*. 2022 Mar;6:7. doi: 10.21037/aot-21-8. Epub 2021 Mar 30. PMID: 34151187; PMCID: PMC8211102.

Anderson T, Wideman L, Cadebiani FA, Kater CE. Effects of Overtraining Status on the Cortisol Awakening Response-Endocrine and Metabolic Responses on Overtraining Syndrome (EROS-CAR). *Int J Sports Physiol Perform*. 2021 Mar 3:1-9. doi: 10.1123/ijsp.2020-0205. Epub ahead of print. PMID: 33662935. (I.F. 3.528)

Cadebiani F, Lin EM, Goren A, Wambier CG. Potential risk for developing severe COVID-19 disease among anabolic steroid users. *BMJ Case Rep*. 2021 Feb 26;14(2):e241572. doi: 10.1136/bcr-2021-241572. PMID: 33637513; PMCID: PMC7919571.

Cadebiani FA, Lim RK, Goren A, McCoy J, Situm M, Kovacevic M, Vaño Galván S, Sinclair R, Tosti A, Wambier CG. Clinical symptoms of hyperandrogenic women diagnosed with COVID-19. *J Eur Acad Dermatol Venereol*. 2021 Feb;35(2):e101-e104. doi: 10.1111/jdv.17004. Epub 2020 Nov 8. PMID: 33089570.

Goren A, Cadebiani FA, Wambier CG, Vano-Galvan S, Tosti A, Shapiro J, Mesinkovska NA, Ramos PM, Sinclair R, Lupi O, Hercogova J, McCoy J. Androgenetic alopecia may be associated with weaker COVID-19 T-cell immune response: An insight into a potential COVID-19 vaccine booster. *Med Hypotheses*. 2021 Jan;146:110439. doi: 10.1016/j.mehy.2020.110439. Epub 2020 Nov 28. PMID: 33308937; PMCID: PMC7695567. (I.F. 1.375)

Cadebiani FA, Silva PHL, Abrao TCP, Kater CE. Novel Markers of Recovery From Overtraining Syndrome: The EROS-LONGITUDINAL Study. *Int J Sports Physiol Perform*. 2021 Jan 5:1-10. doi: 10.1123/ijsp.2020-0248. Epub ahead of print. PMID: 33406484. (I.F. 3.528)

Cadebiani FA, Zimmerman RA, Campello de Souza B, McCoy J, Pereira E Costa RA, Gustavo Wambier C, Goren A. The AndroCoV Clinical Scoring for COVID-19 Diagnosis: A Prompt, Feasible, Costless, and Highly Sensitive Diagnostic Tool for COVID-19 Based on a 1757-Patient Cohort. *Cureus*. 2021 Jan 7;13(1):e12565. doi: 10.7759/cureus.12565. PMID: 33437562; PMCID: PMC7793341.

McCoy J, Cadebiani FA, Wambier CG, Herrera S, Vaño-Galván S, Mesinkovska NA, Ramos PM, Shapiro J, Sinclair R, Tosti A, Goren A. 5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia. *J Eur Acad Dermatol Venereol*. 2021 Apr;35(4):e243-e246. doi: 10.1111/jdv.17021. Epub 2020 Nov 22. PMID: 33135263. (I.F. 5.248)

Goren A, Wambier CG, Herrera S, McCoy J, Vaño-Galván S, Gioia F, Comeche B, Ron R, Serrano-Villar S, Ramos PM, Cadebiani FA, Kovacevic M, Tosti A, Shapiro J, Sinclair R. Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men. *J Eur Acad Dermatol Venereol*. 2021 Jan;35(1):e13-e15. doi: 10.1111/jdv.16953. Epub 2020 Oct 21. PMID: 32977363; PMCID: PMC7536996. (I.F. 5.248)

McCoy J, Wambier CG, Herrera S, Vaño-Galván S, Gioia F, Comeche B, Ron R, Serrano-Villar S, Iwasior RM, Tayeb MA, Cadebiani FA, Mesinkovska NA, Shapiro J, Sinclair R, Goren A. Androgen receptor genetic variant predicts COVID-19 disease severity: a prospective longitudinal study of hospitalized COVID-19 male patients. *J Eur Acad Dermatol Venereol*. 2021 Jan;35(1):e15-e17. doi: 10.1111/jdv.16956. Epub 2020 Oct 21. PMID: 32977355; PMCID: PMC7536899. (I.F. 5.248)

Zimerman RA, Cadebiani FA, Pereira E Costa RA, Goren A, Campello de Souza B. Stay-At-Home Orders Are Associated With Emergence of Novel SARS-CoV-2 Variants. *Cureus*. 2021 Mar 11;13(3):e13819. doi: 10.7759/cureus.13819. PMID: 33728228; PMCID: PMC7949745.

Cadebiani FA, Wambier CG, Goren A. Spironolactone: An Anti-androgenic and Anti-hypertensive Drug That May Provide Protection Against the Novel Coronavirus (SARS-CoV-2) Induced Acute Respiratory Distress Syndrome (ARDS) in COVID-19. *Front Med (Lausanne)*. 2020 Jul 28;7:453. doi: 10.3389/fmed.2020.00453. PMID: 32850920; PMCID: PMC7399048. (I.F.: 3.113)

Cadebiani FA, Goren A, Wambier CG. Spironolactone may provide protection from SARS-CoV-2: Targeting androgens, angiotensin converting enzyme 2 (ACE2), and renin-angiotensin-aldosterone system (RAAS). *Med Hypotheses*. 2020 Oct;143:110112. doi: 10.1016/j.mehy.2020.110112. Epub 2020 Jul 16. PMID: 32721806; PMCID: PMC7363620. (I.F.: 1.375)

Wambier CG, Mehta N, Goren A, Cadebiani FA. COVID-19, androgens, and androgenetic alopecia. *Derm Rev*. 2020;1-8. First published: 23 December 2020/ DOI: <https://doi.org/10.1002/der2.50>

Cadebiani FA. Repurposing existing drugs for COVID-19: an endocrinology perspective. *BMC Endocr Disord*. 2020 Sep 29;20(1):149. doi: 10.1186/s12902-020-00626-0. PMID: 32993622; PMCID: PMC7523486.

Cadebiani FA, Kater CE. Eating, Sleep, and Social Patterns as Independent Predictors of Clinical, Metabolic, and Biochemical Behaviors Among Elite Male Athletes: The EROS-PREDICTORS Study. *Front Endocrinol (Lausanne)*. 2020;11:414. Published 2020 Jun 26. doi:10.3389/fendo.2020.00414. (I.F.: 3.644)

Cadebiani FA. Can spironolactone be used to prevent COVID-19-induced acute respiratory distress syndrome in patients with hypertension?. *Am J Physiol Endocrinol Metab*. 2020;318(5):E587-E588. doi:10.1152/ajpendo.00136.2020. (I.F.: 4.125)

Cadebiani FA, da Silva PHL, Abrao TCP, Kater CE. Diagnosis of Overtraining Syndrome: Results of the Endocrine and Metabolic Responses on Overtraining Syndrome Study: EROS-DIAGNOSIS. *J Sports Med (Hindawi Publ Corp)*. 2020;2020:3937819. Published 2020 Apr 22. doi:10.1155/2020/3937819.

Cadebiani FA, Kater CE. Inter-correlations Among Clinical, Metabolic, and Biochemical Parameters and Their Predictive Value in Healthy and Overtrained Male Athletes: The EROS-CORRELATIONS Study. *Front Endocrinol (Lausanne)*. 2019;10:858. Published 2019 Dec 10. doi:10.3389/fendo.2019.00858. (I.F.: 3.644)

Cadebiani FA, Kater CE. Enhancement of hypothalamic-pituitary activity in male athletes: evidence of a novel hormonal mechanism of physical conditioning. *BMC Endoc Dis*. 2019 Nov 1;19(1):117. Published 2019 Nov 1. doi:10.1186/s12902-019-0443-7. (FI: 2,027)

Cadebiani FA, Kater CE. Novel causes and consequences of overtraining syndrome: the EROS-DISRUPTORS study. *BMC Sports Sci Med Rehabil*. 2019 Sep 18;11:21. doi: 10.1186/s13102-019-0132-x. (FI: 1,088)

Cadegiani FA, Kater CE. Novel insights of overtraining syndrome discovered from the EROS study. *BMJ Open Sport Exerc Med*. 2019 Jun 20;5(1):e000542. doi: 10.1136/bmjsem-2019-000542. (FI: 2,413)

Cadegiani FA, Kater CE, Gazola M. Clinical and biochemical characteristics of high-intensity functional training (HIFT) and overtraining syndrome: findings from the EROS study (The EROS-HIFT). *J Sports Sci*. 2019 Feb 20:1-12. doi: 10.1080/02640414.2018.1555912. (FI: 2,733)

Cadegiani FA, Kater CE. Body composition, metabolism, sleep, psychological and eating patterns of overtraining syndrome: results of the EROS study (EROS-PROFILE). *J Sports Sci*. 2018 Aug;36(16):1902-1910. doi: 10.1080/02640414.2018.1424498. PMID: 29313445. (FI: 2,733)

Cadegiani FA, Kater CE. Basal Hormones and Biochemical Markers as Predictors of Overtraining Syndrome in Male Athletes: The EROS-BASAL Study. *J Athl Train*. 2019 Aug;54(8):906-914. doi: 10.4085/1062-6050-148-18. (FI: 2,319)

Cadegiani FA, Kater CE. Hypothalamic-pituitary-adrenal (HPA) axis functioning in overtraining syndrome: findings from Endocrine and Metabolic Responses on Overtraining Syndrome (EROS) - EROS-HPA axis. *Sports Med Open*. 2017 Dec 8;3(1):45. DOI: 10.1186/s40798-017-0113-0. PMID: 29222606. (FI: 7,074)

Cadegiani FA, Kater CE. Hormonal responses to a non-exercise stress test in athletes with overtraining syndrome: results from the Endocrine and metabolic Responses on Overtraining Syndrome (EROS) - EROS-STRESS. *J Sci Med Sport*. 2018 Jul;21(7):648-653. DOI: 10.1016/j.jsams.2017.10.033. PMID: 29157780. (FI: 3,929)

Cadegiani FA, Kater CE. Hormonal aspects of overtraining syndrome: a systematic review. *BMC Sports Sci Med Rehabil*. 2017 Aug 2;9:14. DOI: <https://doi.org/10.1186/s13102-017-0079-8> PMID: 28785411. (FI: 1,088)

Cadegiani FA, Kater CE. Adrenal Fatigue does not exist: a Systematic Review. *BMC Endoc Dis*. 2016 Aug. DOI: 10.1186/s12902-016-0128-4. PMID: 27557747. (FI: 2,027)
Cadegiani FA *et al*. Aggressive clinical approach to obesity improves metabolic and clinical outcomes and can prevent bariatric surgery: a single center experience. *BMC Obes*. 2017 Feb 21;4:9. DOI: <https://doi.org/10.1186/s40608-017-0147-3>

Cadegiani FA *et al*. Acarbose promotes remission of both early and late dumping syndromes in post-bariatric patients. *Diabetes Metab Syndr Obes*. 2016 Dec 7;9:443-446. DOI: [10.2147/DMSO.S123244](https://doi.org/10.2147/DMSO.S123244). (F.I. 1,34)

Cadegiani FA. Remission of Severe Myasthenia Gravis After Massive-Dose Vitamin D Treatment. *Am J Case Rep*. 2016; Jan. 17:51-51.

RECENT PMC INDEXED SCIENTIFIC PUBLICATIONS

Cadegiani F, Abrao TPC, da Silva PLH, Kater CE. The “Normal” Hormonal Levels in Athletes: Should Reference Ranges Be Adapted for the Physically Active Population?. *J Endocr Soc*. 2020;4(Suppl 1):MON-LB305. Published 2020 May 8. doi:10.1210/jendso/bvaa046.2321.

Cadegiani F, da Silva PLH, Abrao TPC, Kater CE. Novel Hormonal and Metabolic Markers of Recovery From Overtraining Syndrome Unveiled by the Longitudinal ARM of the Eros Study - the Eros-Longitudinal Study. *J Endocr Soc*. 2020;4(Suppl 1):SAT-LB4. Published 2020 May 8. doi:10.1210/jendso/bvaa046.2337.

Cadegiani F, da Silva PLH. Novel Paradoxical Markers of Weight Loss: Is the Worse Actually the Better? a Retrospective analysis of 1,567 Patients with Obesity With Successful Clinical Weight-Loss Approaches. *J Endocr Soc.* 2020;4(Suppl 1):MON-LB100. Published 2020 May 8. doi:10.1210/jendso/bvaa046.2338.

Cadegiani FA, da Silva PLH. Clinical Guidelines for the Research on the Endocrinology of Physical Activity and Sport. *J Endocr Soc.* 2020;4(Suppl 1):MON-LB311. Published 2020 May 8. doi:10.1210/jendso/bvaa046.2333.

Cadegiani F. 5-Year Data of an Aggressive Pharmacological Approach to Moderate and Morbid Obesity: Is Prevention of Bariatric Surgery Feasible in the Long Run?. *J Endocr Soc.* 2020;4(Suppl 1):MON-LB101. Published 2020 May 8. doi:10.1210/jendso/bvaa046.2340

Cadegiani F, da Silva PLH, Abrao TPC, Kater CE. The Testosterone-To-Estradiol Ratio, Rather Than Testosterone or Estradiol Alone, Is a More Precise Marker of Metabolic-Related Outcomes in Males: Insights From a Systematic Review. *J Endocr Soc.* 2020;4(Suppl 1):SAT-LB8. Published 2020 May 8. doi:10.1210/jendso/bvaa046.2293.

RECENT REMARKABLE ACHIEVEMENTS

- Author of the first protocol scientifically validated for prevention of Bariatric Surgery through intensive clinical therapy for long-term weight loss
- Largest successful rate of the responses to clinical treatment of moderate and morbid obesity reported to date
- Game changer in the methodology of the research on endocrinology of the physical activity & sport
- Largest attention score from general media and audience of a study in the Endocrinology field in the world (among papers published at the BMC Endocrine Disorders, according to altmetric.com, the most recognized method to measure the attention score. Eg of journals and media: The Washington Post, Seattle Times, Harvard Medical School news) (Cadegiani FA, Kater CE. Adrenal Fatigue does not Exist: a Systematic Review. *BMC Endoc Dis* 2016;Aug:2-9.
- Fastest PhD degree in the history of Federal University of São Paulo (final grade: 100/100) (duration: 07 months, including a special authorization to shorten the period spent on PhD)
- Main Editor of the first research topic on the Endocrinology of Physical Activity and Sport in the medical literature
- Editor of three high-impact factor indexed journals:

Associate Editor at BMC Endocrine Disorders;

Guest Editor at Frontiers in Medicine;

Guest Editor at Frontiers in Endocrinology; and

Guest Editor at BMC Sports Medicine, Science & Rehabilitation

- Mentioned in The Washington Post as the author responsible to debunk the existence of the pseudo-disease termed as “Adrenal Fatigue”.
- Author with the largest number of studies presented in 03 of the 05 last meetings of The Endocrine Society (ENDO 2016, ENDO 2018, and ENDO 2020)
- Author with the largest number of studies presented in last meeting of the American Association of Clinical Endocrinologists (AACE – EMBRAACE 2020)

- Author with the largest number of presented studies among researchers from all the world, at The Obesity Week, 2015, from The Obesity Society (TOS).
- Sole author of the first chapter of a book on liver before and after bariatric surgery ("The liver before and after bariatric surgery", from the book: "Dietary interventions in liver diseases", Elsevier, USA, 2019).
- Author regularly mentioned by the Blackburn Obesity course - Harvard Medical School as a reference for aggressive clinical treatment for obesity.
- Author used as the basis for the novel methodological approaches to hormonal and metabolic aspects of athletes in almost all new researches in Europe, North America, Asia, and Oceania, based on the design innovations of the EROS study.
- 70% of all published papers in PubMed indexed journals in the field of Sports Endocrinology in the last 03 years
- 80% of all published papers in PubMed indexed journals in Overtraining Syndrome in the last 03 years

Latest overseas feedback:

"Thank you, as we are honored to be a part of this very special set of articles. The honor is dedicated to your **great leadership** and **pulling together top scientists** for this special set of papers and this based on your **extraordinary reputation** and getting this done. Congrats to you." **(William Kraemer, professor at the Ohio State University, 2020)**

"very impressed with not only the quantity of research this project has produced, but also the high quality of the research - especially in a topic area that can be extremely challenging. Thank you for continuing to add valuable insights..." **(Travis Anderson, PhD at University of North Carolina at Greensboro, 2020)**

"I was **so impressed by the work** these researchers have done. Congratulations on **excellent work**. I found the premise of the work **insightful and unique**. Good job." **(Anthony C. Hackney, full professor at University of North Carolina at Chapel Hill, 2020)**

"This published work is **very interesting** and also **very complete**. I found it presenting some new and different insights to the Overtraining issue. My congratulations to the authors on their **excellent efforts**." **(Anthony C. Hackney, full professor at University of North Carolina at Chapel Hill, 2020)**

"Among the **three most expert obesity specialists in the clinical management of morbid obesity** in the world" (Obesity Week, 2019)

"In only 02 years..."

Alone, he has **published more than whole institutions**.

He **transformed the methodology on hormones & sports**.

He **changed the way we see overtraining syndrome**.

He **changed the way we treat obesity**.

Even working 12-15 hours a day seeing patients, he was capable to review more papers than 99% of the scientists on his field.

Now, he dreams on the creation of a science-breaking and innovative startup, with unprecedented ethical policies and the highest quality standards.

Imagine what he is capable." **(videoconference with University of Sheffield, UK, and Nottingham Trent University, UK 2020)**

(For regulatory reasons, some of the achievements have not made publicly, but can be demonstrated on demand)

JOURNAL EDITOR POSITIONS

Associate editor at BMC Endocrine Disorders.

Guest editor at Frontiers in Endocrinology.

Guest editor at BMC Sports Medicine, Science & Rehabilitation.

Guest editor at Frontiers in Medicine.

RECENT CHAPTERS AT BOOKS:

CADEGIANI F.A. – Chapter: “The liver before and after bariatric surgery”; Book: “Dietary interventions in liver diseases” (Elsevier, 2019)

CADEGIANI F.A. – Chapter: “Overtraining Syndrome”; Book: “Supplements in Clinical Practice: an Endocrine Perspective” (Portuguese) (Clannad, 2018)

MEMBERSHIP IN SCIENTIFIC SOCIETIES:

Specialist Member of The Endocrine Society

Specialist Member of the American Diabetes Association - ADA

Specialist Member of the American association of Clinical Endocrinologists - AACE

Invited Member of The Obesity Society – TOS

Specialist Member of the Brazilian Society of Endocrinology and Metabolism – SBEM

Specialist Member of the Brazilian Association for the Study of Obesity – ABESO

Member of the Brazilian Association of Nutrology - ABRAN

RECENT PRESENTATION AT CONFERENCES:

Cadegiani FA, Abrao TCP, da Silva PHL, Kater CE. The “Normal” Hormonal Levels in Athletes: Should Reference Ranges Be Adapted for the Physically Active Population? 102th Annual Meeting & Expo (ENDO 2020 – Online due to the COVID-19 pandemic) - The Endocrine Society. *J Endocr Soc.* Volume 4, Issue Supplement_1, April-May 2020, MON–LB305. doi: 10.1210/jendso/bvaa046.2321.

Cadegiani FA, da Silva PHL, Abrao TCP, Kater CE. Novel Hormonal and Metabolic Markers of Recovery From Overtraining Syndrome Unveiled by the Longitudinal ARM of the Eros Study - the Eros-Longitudinal Study. 102th Annual Meeting & Expo (ENDO 2020 – Online due to the COVID-19 pandemic) - The Endocrine Society. *J Endocr Soc.* Volume 4, Issue Supplement_1, April-May 2020, SAT-LB4. doi: 10.1210/jendso/bvaa046.2337.

Cadegiani FA, da Silva PHL, Abrao TCP, Kater CE. The Testosterone-To-Estradiol Ratio, Rather Than Testosterone or Estradiol Alone, Is a More Precise Marker of Metabolic-Related Outcomes in Males: Insights From a Systematic Review. 102th Annual Meeting & Expo (ENDO 2020 – Online due to the COVID-19 pandemic) - The Endocrine Society. *J Endocr Soc.* Volume 4, Issue Supplement_1, April-May 2020, SAT-LB8. doi: 10.1210/jendso/bvaa046.2293.

Cadegiani FA, da Silva PHL. Clinical Guidelines for the Research on the Endocrinology of Physical Activity and Sport. 102th Annual Meeting & Expo (ENDO 2020 – Online due to the COVID-19 pandemic) - The Endocrine Society. *J Endocr Soc.* Volume 4, Issue Supplement_1, April-May 2020, MON–LB311. doi: 10.1210/jendso/bvaa046.2333.

Cadegiani FA, da Silva PHL. Novel Paradoxical Markers of Weight Loss: Is the Worse Actually the Better? a Retrospective analysis of 1,567 Patients with Obesity With Successful Clinical Weight-Loss Approaches. 102th Annual Meeting & Expo (ENDO 2020 – Online due to the COVID-19 pandemic) - The Endocrine Society. *J Endocr Soc.* Volume 4, Issue Supplement_1, April-May 2020, MON–LB100. doi: 10.1210/jendso/bvaa046.2338.

Cadegiani FA. 5-Year Data of an Aggressive Pharmacological Approach to Moderate and Morbid Obesity: Is Prevention of Bariatric Surgery Feasible in the Long Run? 102th Annual Meeting & Expo (ENDO 2020 – Online due to the COVID-19 pandemic) - The Endocrine Society. *J Endocr Soc.* Volume 4, Issue Supplement_1, April-May 2020, MON–LB101. doi: 10.1210/jendso/bvaa046.2340.

Cadegiani FA, Kater CE. “Hypothalamic-pituitary-adrenal (HPA) axis functioning in healthy athletes and in overtraining syndrome: findings from Endocrine and Metabolic Responses on Overtraining Syndrome (EROS) - EROS-HPA axis”. 100th Annual Meeting & Expo (ENDO 2018) - The Endocrine Society. 17 a 20 de março. Chicago, IL, EUA. *Endocrine Reviews.* 39(2, suppl). April 2018.

Cadegiani FA, Kater CE. “Growth Hormone (GH) and prolactin responses to a non-exercise stress test in healthy athletes and in athletes with overtraining syndrome: results from the Endocrine and metabolic Responses on Overtraining Syndrome (EROS) - EROS-STRESS”. 100th Annual Meeting & Expo (ENDO 2018) - The Endocrine Society. 17 a 20 de março. Chicago, IL, EUA. *Endocrine Reviews.* 39(2, suppl). April 2018.

Cadegiani FA, Kater CE. “Basal hormones and biochemical markers as predictors of overtraining syndrome: results from the Endocrine and metabolic Responses on Overtraining Syndrome (EROS) study — EROS-BASAL”. 100th Annual Meeting & Expo (ENDO 2018) - The Endocrine Society. 17 a 20 de março. Chicago, IL, EUA. *Endocrine Reviews.* 39(2, suppl). April 2018.

Cadegiani FA, Kater CE. “Body composition, metabolism, sleep, psychological and eating patterns in healthy athletes and in overtraining syndrome: results of the Endocrine and metabolic Responses in Overtraining Syndrome (EROS) study (EROS-PROFILE)”. 100th Annual Meeting & Expo (ENDO 2018) - The Endocrine Society. 17 a 20 de março. Chicago, IL, EUA. *Endocrine Reviews.* 39(2, suppl). April 2018.

Cadegiani FA, Kater CE. “Hormonal conditioning: a new concept on athletic training”. 100th Annual Meeting & Expo (ENDO 2018) - The Endocrine Society. 17 a 20 de março. Chicago, IL, EUA. *Endocrine Reviews.* 39(2, suppl). April 2018.

Cadegiani FA, Kater CE. “Defining the underlying features of overtraining syndrome: deconditioning of optimized hormonal and metabolic responses in athletes”. 100th Annual Meeting & Expo (ENDO 2018) - The Endocrine Society. 17 a 20 de março. Chicago, IL, EUA. *Endocrine Reviews.* 39(2, suppl). April 2018.

Cadegiani FA, Kater CE. Hormonal conditioning: A new concept on athletic training. *Arch Endocrinol Metab.* 2018;62(Suppl 04):S8. Resumo 66933.

Cadegiani FA, Kater CE. Defining the underlying features of overtraining syndrome: Deconditioning of optimized hormonal and metabolic responses in athletes. *Arch Endocrinol Metab.* 2018;62(Suppl 04):S110. Resumo 66934.

Cadegiani FA, Kater CE, Gazola M. Clinical and biochemical characteristics of high-intensity functional training and overtraining syndrome with CrossFit: EROS-CROSSFIT,

a *post-hoc* analysis of the Endocrine and metabolic Responses in Overtraining Syndrome (EROS) study. *Arch Endocrinol Metab.* 2018;62(Suppl 04):S109. Resumo 66939.

Cadegiani FA, Kater CE. Hypothalamic-pituitary-adrenal (HPA) axis functioning in overtraining syndrome: Findings from the Endocrine and metabolic Responses on Overtraining Syndrome (EROS) study – EROS-HPA AXIS. *Arch Endocrinol Metab.* 2018;62(Suppl 04): S111. Resumo 66940.

Cadegiani FA, Kater CE. Body composition, metabolism, sleep, psychological and eating patterns of overtraining syndrome: Results of the Endocrine and metabolic Responses on Overtraining Syndrome (EROS) study - (EROS-PROFILE). *Arch Endocrinol Metab.* 2018;62(Suppl 04):S8. Resumo 66943.

Cadegiani FA, Kater CE. Basal hormones and biochemical markers as predictors of overtraining syndrome: EROS-BASAL – Results from the Endocrine and metabolic Responses on Overtraining Syndrome study. *Arch Endocrinol Metab.* 2018;62(Suppl 04):S109. Resumo 66946.

CADEGIANI, F. A.. Short-term follow up of Gold Standard Body Analysis Surveillance? protocol: The role of surveillance in the efficacy of obesity intervention.. Poster Presentation - 3rd Obesity Week – The American Obesity Meeting – Los Angeles, CA, EUA – November/2015.

CADEGIANI, F. A.. A continuous surveillance and follow-up can perpetuate weight loss after discontinuing drugs for obesity. Poster Presentation - 3rd Obesity Week – The American Obesity Meeting – Los Angeles, CA, EUA – November/2015.

CADEGIANI, F. A.. A new approach to the obese patient: An intensive and comprehensive therapy joining different modalities can bring significant results. Poster Presentation - 3rd Obesity Week – The American Obesity Meeting – Los Angeles, CA, EUA – November/2015.

CADEGIANI, F. A.. An aggressive clinical approach may prevent bariatric surgery. Poster Presentation - 3rd Obesity Week – The American Obesity Meeting – Los Angeles, CA, EUA – November/2015.

CADEGIANI, F. A.; DINIZ, G. C. . Metabolic outcomes of an intensive lifestyle, behavioral and pharmacological intervention protocol for preventing bariatric surgery. Poster Presentation - 3rd Obesity Week – The American Obesity Meeting – Los Angeles, CA, EUA – November/2015.

CADEGIANI, F. A.; DINIZ, G. C. ; ALVES, G. F. P. C. . Metabolic syndrome and obesity resolution as a result of an intensive multimodal obesity intervention protocol. Poster Presentation - 3rd Obesity Week – The American Obesity Meeting – Los Angeles, CA, EUA – November/2015.

CADEGIANI, F. A.; MACEDO, G. B. . A quadruple anti-diabetic association may present significant results in patients unresponsive to diet and exercise. Poster Presentation - 3rd Obesity Week – The American Obesity Meeting – Los Angeles, CA, EUA – November/2015.

CADEGIANI, F. A.. A powerful probiotic can improve fat weight loss in refractory patients. Poster Presentation - 3rd Obesity Week – The American Obesity Meeting – Los Angeles, CA, EUA – November/2015.

CADEGIANI, F. A.. A review over evaluation methods of response to obesity therapies? Are scientific and medical communities too "weight-centered"? Poster Presentation - 3rd Obesity Week – The American Obesity Meeting – Los Angeles, CA, EUA – November/2015.

CADEGIANI, F. A.. Indications for bariatric surgery ? Are some doctors going too far? Poster Presentation - 3rd Obesity Week – The American Obesity Meeting – Los Angeles, CA, EUA – November/2015.

CADEGIANI, F. A.; KATER, C. E. . Adrenal Fatigue: Myth or Reality? A Systematic Review. Poster Presentation – The 98th Annual Meeting of The Endocrine Society – (ENDO 2016). Boston, MA, EUA – April/2016.

CADEGIANI, F. A.; KATER, C. E. . Hormonal Aspects in Overtraining Syndrome: A Systematic Review. Poster Presentation – The 98th Annual Meeting of The Endocrine Society (ENDO 2016). Boston, MA, EUA – April/2016.

CADEGIANI, F. A.. Non Alcoholic Steatohepatitis (NASH) Resolution with Obesity Therapy: Should Obesity be Treated Prior to Specific Nash Treatment in All Obese Patients? Poster Presentation – The 98th Annual Meeting of The Endocrine Society (ENDO 2016). Boston, MA, EUA – April/2016.

CADEGIANI, F. A.. Weight Loss Among Hormonally Compensated Hypothyroidism Obese Patients Unresponsive to Obesity Therapy after Addition of Liothyronine (T3). May T3 be Helpful in Selected Patients? Poster Presentation. The 98th Annual Meeting of The Endocrine Society (ENDO 2016). Boston, MA, EUA – April/2016.

CADEGIANI, F. A.. Use of Liothyronine in Hormonally Compensated but Clinically Persistent Hypothyroidism: A Matter of Patient Selection? Poster Presentation – The 98th Annual Meeting of The Endocrine Society – Endo 2016 – Boston, MA – April/2016.

CADEGIANI, F. A.; DINIZ, G. C. ; ALVES, G. F. P. C. ; MACEDO, G. B. . T2DM, NASH, Hypertension, Hypertriglyceridemia, Metabolic Syndrome And Morbid Obesity, A Harmful Sextuple : Complete Remission Of Multiple Disorders By Clinical Intervention Against Obesity. Poster Presentation – The International Congress on Obesity – ICO 2016 – World Obesity – Vancouver, Canada – May/2016.

CADEGIANI, F. A.. Low Dose Of Anabolic Steroid (AS) Oxandrolone For Sarcopenic Post-bariatric Patients Can Be Safe And Effective. Poster Presentation – The International Congress on Obesity – ICO 2016 – World Obesity – Vancouver, Canada – May/2016.

CADEGIANI, F. A.. Anabolic Steroid (AS) Nandrolone In Sarcopenic Post-bariatric Patients: Does It Improve Appearance, Protein Absorption And Synthesis And Muscle Mass? Poster Presentation – The International Congress on Obesity – ICO 2016 – World Obesity – Vancouver, Canada – May/2016.

CADEGIANI, F. A.. Effects Of GLP-1 Analogue As An Add-on Therapy On Obesity Therapy: Does It Enhance Results? Poster Presentation – The International Congress on Obesity – ICO 2016 – World Obesity – Vancouver, Canada – May/2016.

CADEGIANI, F. A.. Effects Of SGLT-2 Inhibitors As An Add-on Therapy On Obesity Therapy With GLP-1 Analogues: Does It Help Improve Outcomes?. 2016. Apresentação de Trabalho/Congresso - The International Congresso n Obesity – ICO 2016 – World Obesity – Vancouver, Canada – May/2016.

CADEGIANI, F. A.; SILVA, O. S. . SGLT-2 Inhibitors (SGLT2i) As Monotherapy Against Obesity: Is It Feasible? Poster Presentation – The International Congress on Obesity – ICO 2016 – World Obesity – Vancouver, Canada – May/2016.

CADEGIANI, F. A.. Metabolic Outcomes Of Association Of GLP-1 And SGLT-2 In Obese Pre-diabetic Patients. Poster Presentation – The International Congress on Obesity – ICO 2016 – World Obesity – Vancouver, Canada – May/2016.

CADEGIANI, F. A.. Slow Interruption Of Drugs Against Obesity Can Be An Effective Method To Prevent Obesity Relapse Poster Presentation – The International Congress on Obesity – ICO 2016 – World Obesity – Vancouver, Canada – May/2016.

CADEGIANI, F. A.. GLP-1 Analogue (GLP1a) And SGLT-2 Inhibitor (SGLT2i) Double Therapy In Patients Unresponsive To Current On-label Therapy Against Obesity: A Powerful And Effective Association. Poster Presentation – The International Congress on Obesity – ICO 2016 – World Obesity – Vancouver, Canada – May/2016.

CADEGIANI, F. A.. Psychotherapy In Obesity Intervention: Does It Matter? Poster Presentation – The International Congress on Obesity – ICO 2016 – World Obesity – Vancouver, Canada – May/2016.

CADEGIANI, F. A.. Acarbose Can Promote Complete Remission Of Both Early And Late Dumping Syndromes And Increase Exercise Capacity In Post-bariatric Patients. Poster Presentation – The International Congress on Obesity – ICO 2016 – World Obesity – Vancouver, Canada – May/2016.

CADEGIANI, F. A.; DINIZ, G. C. A Different Protocol Using Liraglutide For Obesity Can Be As Efficient, Promote Less Symptoms And Withdraw And Be Less Expensive Than Standardized Protocol. Poster Presentation – The International Congress on Obesity – ICO 2016 – World Obesity – Vancouver, Canada – May/2016.

RECENT SPEAKER ACTIVITIES

A vida pós-COVID-19. Arnold Conference. Live presentation. April/2020

Fadiga Adrenal: Existe ou é Mito? XXIII Congresso Brasileiro de Nutrologia – Associação Brasileira de Nutrologia (ABRAN) – São Paulo, SP, Brasil – Setembro/2019.

Fadiga adrenal: mito ou realidade?. Arnold Conference. São Paulo, SP, Brazil - April/2018

Exercise as Medicine and Sports Endocrinology. 15th International Congress of Natural Medicine. Melbourne, Australia – June/2018.

Andropause & Men's Health. 15th International Congress of Natural Medicine. Melbourne, Australia – June/2018.

Adrenal Fatigue: Myth or Reality. 15th International Congress of Natural Medicine. Melbourne, Australia – June/2018.

Growth hormone (GH) and prolactin responses to a non-exercise stress test in athletes with overtraining syndrome: Results from the Endocrine and metabolic Responses on Overtraining Syndrome (EROS) study –EROS-STRESS. (Published as: *Arch Endocrinol Metab.* 2018;62(Suppl 04):S110. Resumo 66941).

Hypothalamic-pituitary-adrenal (HPA) axis functioning in healthy athletes and in overtraining syndrome: findings from Endocrine and Metabolic Responses on Overtraining Syndrome (EROS) - EROS-HPA axis". 100th Annual Meeting & Expo (ENDO 2018) - The Endocrine Society. 17 a 20 de março. Chicago, IL, EUA. . (Published as: *Endocrine Reviews*. 39(2, suppl). April 2018).

Qual a vez da dieta, nutrientes, medicamentos e cirurgia na obesidade? (When is the time for nutrients, medications, and surgery in obesity management?). 4th Lifestyle Summit Brazil – São Paulo, Brazil – Nov/2017.

Exercício físico como remédio: resultados do EROS study (Physical activity as the best medication: results of the EROS study). 4th Lifestyle Summit Brazil – São Paulo, Brazil – Nov/2017.

Effects Of Double Introduction Of GLP-1 Analogue (GLP1a) And SGLT-2 Inhibitor (SGLT2i) In Diabetic Obese Patients Already Under Therapy Against T2DM: A Promising Future? ORAL PRESENTATION – The International Congress on Obesity – ICO 2016 – World Obesity – Vancouver, Canada – May/2016.

RECENT CONFERENCES

The 100th Annual Meeting & Expo - The Endocrine Society (ENDO 2018). Chicago, IL, EUA – March/2018.

The 98th Annual Meeting & Expo - The Endocrine Society (ENDO 2016). Boston, MA, EUA – April/2016.

The 96th Annual Meeting & Expo - The Endocrine Society (ENDO 2014). Chicago, IL, EUA – June/2014.

The 93th Annual Meeting & Expo - The Endocrine Society (ENDO 2011). Boston, MA, EUA – June/2011.

20th European Congress of Endocrinology – European Society of Endocrinology (ECE 2018) – Barcelona, Spain – May/2018.

17th European Congress of Endocrinology – European Society of Endocrinology (ECE 2015) – Dublin, Ireland – May/2015.

The 79th Scientific Sessions – American Diabetes Association (ADA 2019). San Francisco, CA, EUA – June/2019.

The 77th Scientific Sessions – American Diabetes Association (ADA 2017). San Diego, CA, EUA – June/2017.

The 74th Scientific Sessions – American Diabetes Association (ADA 2014). San Francisco, CA, EUA – June/2014.

54th Annual Meeting of the European Association for the Study of Diabetes (EASD 2018). Berlin, Germany – October/2018.

51th Annual Meeting of the European Association for the Study of Diabetes (EASD 2015). Stockholm, Sweden – September/2015.

7th ObesityWeek - 37th Annual Scientific Meeting of The Obesity Society & 36th ASMBS Annual Meeting – The Obesity Society (OBESITY WEEK 2019). Las Vegas, NV, EUA – November/2019.

6th ObesityWeek – 36th Annual Scientific Meeting of The Obesity Society & 35th ASMBS Annual Meeting – The Obesity Society (OBESITY WEEK 2018). Nashville, TN, EUA – November/2018.

5th ObesityWeek - 35th Annual Scientific Meeting of The Obesity Society & 34th ASMBS Annual Meeting – The Obesity Society (OBESITY WEEK 2017). Washington, DC, EUA – November/2017.

4th ObesityWeek - 34th Annual Scientific Meeting of The Obesity Society & 33rd ASMBS Annual Meeting – The Obesity Society (OBESITY WEEK 2016). New Orleans, LA, EUA – November/2016.

3rd ObesityWeek – 33rd Annual Scientific Meeting of The Obesity Society & 32nd ASMBS Annual Meeting – The Obesity Society (OBESITY WEEK 2015). Los Angeles, CA, EUA – November/2015.

26th - European Congress on Obesity – European Association for the Study of Obesity (EASO 2019) – Glasgow, Scotland – April/2019.

25th - European Congress on Obesity – European Association for the Study of Obesity (EASO 2019) – Vienna, Austria – May/2018.

The International Congress on Obesity - World Obesity (ICO 2016). Vancouver, Canada – May/2016.

33º Congresso Brasileiro de Endocrinologia – Sociedade Brasileira de Endocrinologia (CBEM 2018) – Belo Horizonte, MG, Brasil – Agosto/2018.

32º Congresso Brasileiro de Endocrinologia – Sociedade Brasileira de Endocrinologia (CBEM 2016) – Costa do Sauípe, BA, Brasil – Setembro/2016.

31º Congresso Brasileiro de Endocrinologia – Sociedade Brasileira de Endocrinologia (CBEM 2014) – Curitiba, PR, Brasil – Setembro/2014.

30º Congresso Brasileiro de Endocrinologia – Sociedade Brasileira de Endocrinologia (CBEM 2012) – Goiânia, GO, Brasil – Novembro/2012.

Congresso Brasileiro de Obesidade – Associação Brasileira para o Estudo da Obesidade (ABESO) – Recife, PE, Brasil – Março/2017.

Congresso Brasileiro de Atualização em Endocrinologia – Sociedade Brasileira de Endocrinologia (CBAEM 2013). Natal, RN, Brasil – Agosto/2013.

XVIII Congresso Brasileiro de Diabetes – Sociedade Brasileira de Diabetes (SBD 2011) – Brasília, DF, Brasil – Novembro/2011.

XXIII Congresso Brasileiro de Nutrologia – Associação Brasileira de Nutrologia (ABRAN) – São Paulo, SP, Brasil – Setembro/2019.

XVIII Congresso Brasileiro de Nutrologia – Associação Brasileira de Nutrologia (ABRAN)

– São Paulo, SP, Brasil – Setembro/2014.

MEDICAL MATERIAL

Obesidade e hipogonadismo: um ciclo a ser quebrado. UPDATE Terapia Hormonal do Homem. Eurofarma. Ano 1 – No 4 – Setembro/2019.

Capítulo: Overtraining. Suplementos, Exercícios e Esporte – Uma Visão Endocrinológica. Editora Clannad. Lançamento: Agosto/2018.

SOCIAL MEDIA

1. ResearchGate - https://www.researchgate.net/profile/Cadegiani_Flavio
2. Publons - <https://publons.com/researcher/1555373/flavio-cadegiani/>
3. LinkedIn - <https://www.linkedin.com/in/flávio-a-cadegiani-0b73a1aa/>
4. Twitter - @FlavioCadegiani
5. Facebook - @drflaviocadegiani (in transition from Portuguese to English)
6. ORCID - [0000-0002-2699-4344](https://orcid.org/0000-0002-2699-4344)
7. Web of Science ResearcherID - [O-3289-2019](https://www.researcherid.com/rid/O-3289-2019)

RECENT RELEVANCE ON INTERNATIONAL MEDIA

<https://www.verywellhealth.com/adrenal-fatigue-exhaustion-3231648>

<https://www.verywellfit.com/running-and-not-losing-weight-2911110>

<https://www.t-nation.com/training/tip-axial-loading-what-you-need-to-know>

<https://www.t-nation.com/training/6-changes-veteran-lifters-need-to-make>

<https://articles.a1supplements.com/supplements/supplement-research/make-stimulants-pre-workout-stronger/>

<https://www.uptodate.com/contents/overtraining-syndrome-in-athletes>

<https://lymescience.org/coinfection-confusion/>

<http://www.news24xx.com/read/news/2960/The-tragic-story-of-worlds-tallest-12-year-old-boy->

<https://hvmn.com/blog/training/overtraining-syndrome-can-sabotage-performance>

<https://www.irunfar.com/2018/12/beyond-fatigue-understanding-overtraining-syndrome.html>